Alexander Perl, MD, provides an overview of the standard of care for AML and ALL as reflected in clinical reports originating at ASH 2016. In discussing AML, Dr. Perl considers therapy selection in patients age >65 —CPX-351 for fitter older patients with newly diagnosed high-risk AML and secondary AML; vadastuximab and hypomethalation in frontline AML; venetoclax + LDAC in treatment naïve AML—as well as FLT3 inhibition in newly diagnosed mutant AML for younger patients.
Published
February 14, 2018
Created by
BROADCASTMED